CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2025
0mins
Source: Globenewswire
Collaboration Announcement: CytoMed Therapeutics has entered into a Business & Research Collaboration Agreement with SunAct Cancer Institute to conduct clinical trials in India, focusing on the safety and efficacy of allogeneic gamma delta T cells for cancer treatment.
Research Goals and Impact: The collaboration aims to provide affordable cancer therapies, enhance access to treatments in India, and contribute valuable data to the global fight against cancer, while leveraging local expertise and regulatory support.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
